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Abstract
The response of human epidermal growth factor receptor2 (HER2)- positive breast cancer (BC) patients to anti-HER2
targeted therapy is significant. However, the response is not uniform and a proportion of HER2-positive patients do not
respond. This study aims to identify predictors of response in the neoadjuvant treatment and to assess the discordance
rate of HER2 status between pre- and post-treatment specimens in HER2-positive BC patients. The study group
comprised 500 BC patients treated with neoadjuvant chemotherapy (NACT) and/or neoadjuvant anti-HER2 therapy and
surgery who had tumours that were 3+ or 2+ with HER2 immunohistochemistry (IHC). HER2 IHC 2+ tumours were
classified into five groups by fluorescence in situ hybridisation (FISH) according to the 2018 ASCO/CAP guidelines of
which Groups 1, 2 and 3 were considered HER2 amplified. Pathological complete response (pCR) was more frequent in
HER2 IHC 3+ tumours than in HER2 IHC 2+/HER2 amplified tumours, when either in receipt of NACT alone (38%
versus 13%; p= 0.22) or neoadjuvant anti-HER2 therapy (52% versus 20%; p < 0.001). Multivariate logistic regression
analysis showed that HER2 IHC 3+ and histological grade 3 were independent predictors of pCR following neoadjuvant
anti-HER2 therapy. In the HER2 IHC 2+/HER2 amplified tumours or ASCO/CAP FISH Group 1 alone, ER-negativity
was an independent predictor of pCR following NACT and/or neoadjuvant anti-HER2 therapy. In the current study, 22%
of HER2-positive tumours became HER2-negative by IHC and FISH following neoadjuvant treatment, the majority
(74%) HER2 IHC 2+/HER2 amplified tumours. Repeat HER2 testing after neoadjuvant treatment should therefore be
considered.
Introduction
Approximately 15% of invasive breast cancers (BCs) are
human epidermal growth factor receptor2 (HER2) positive,
defined as showing HER2 gene amplification or protein
overexpression, and such tumours have been shown to be
sensitive to anti-HER2 targeted therapy [1–3]. Currently, a
combination of sequential chemotherapy and anti-HER2
therapy is the standard treatment for HER2-positive BC
both in the neoadjuvant and adjuvant setting [4]. Immuno-
histochemistry (IHC) and/or in situ hybridisation (ISH) is
routinely used to evaluate the HER2 status for treatment
selection.
The current American Society of Clinical Oncology/
College of American Pathologists (ASCO/CAP) guidelines
regard HER2 IHC score 3+ as positive, score 2+ as equi-
vocal and scores 0 and 1+ as negative [5]. If the IHC result
is score 2+, such patients are tested for HER2 amplification
by ISH; most commonly fluorescence in situ hybridisation
(FISH), to assess the average HER2 gene and chromosome
enumeration probe 17 (CEP17) copy numbers (CNs) per
carcinoma cell and the ratio of these [5]. The 2018 ASCO/
CAP guidelines divide HER2 FISH status into five groups
(Table 1) [5].
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For HER2-positive BC, defined as either IHC 3+ or IHC
2+ with HER2 amplification, neoadjuvant chemotherapy
(NACT) plus neoadjuvant anti-HER2 therapy is an effective
treatment option [4]. The pathological complete response
(pCR) rate at the time of surgery is commonly used as an
endpoint in clinical trials and a predictor of good prognosis
in HER2-positive BC with neoadjuvant treatment [6–8].
The most widely-agreed definition of pCR is no residual
invasive carcinoma both in the breast and axillary lymph
nodes regardless of the presence of residual ductal carci-
noma in situ (DCIS) (ypT0/is ypN0) [8].
Retrospective studies of HER2-positive BC patients who
have received NACT plus neoadjuvant anti-HER2 therapy
have reported a higher rate of pCR in IHC 3+ compared to
IHC 2+/HER2 amplified tumours [9]. However, little
attention has been paid to predictors of pCR among the
different ASCO/CAP FISH groups. In addition, some
clinical trials showed that pCR rates are lower in oestrogen
receptor (ER)-positive/HER2-positive BC than in ER-
negative/HER2-positive BC [10–12]. It remains unclear if
this holds true for the different ASCO/CAP FISH amplified
groups.
Meanwhile, others studies have reported discordant
HER2 status between the pre-treatment biopsy and the post-
treatment surgical specimen [13–18]. Loss of HER2-
positivity in the residual tumour has been reported to be
associated with a poorer outcome compared to tumours that
remain HER2-positive following neoadjuvant treatment
[16–18]. The change in HER2 status may also affect the
selection of post-neoadjuvant treatment. However, there is
no consensus on whether or not repeat HER2 testing in
post-neoadjuvant residual disease should be performed in
routine practice.
In this study, we have analysed 500 invasive BCs with
HER2 IHC 3+, or IHC 2+ for which HER2 FISH data were
available, from patients who received NACT and/or
neoadjuvant anti-HER2 therapy with subsequent therapeutic
surgery. Our aim was to evaluate the relationship between
HER2 categories and pCR alongside other variables. We
also report the level of concordance for HER2 and the
ASCO/CAP FISH groups between the pre- and post-
treatment specimens in this study cohort.
Materials and methods
Study cohort
A total of 500 invasive BCs with HER2 IHC 3+ or IHC 2+
for which HER2 FISH data were available from patients
who received NACT and/or neoadjuvant anti-HER2 therapy
with subsequent therapeutic surgery between 2013 and
2020 were included. Exclusion criteria were: (1) no infor-
mation of HER2 gene CN or HER2/CEP17 ratio in pre-
treatment specimens for IHC 2+ tumours; (2) patients
treated with neoadjuvant hormonal therapy alone; (3) lack
of data on pathological response in the surgical specimen.
Therefore 75 of the 575 patients were excluded. The
majority of patients were treated at Nottingham University
Hospitals NHS Trust, Nottingham (n= 254) with additional
patients from the following nine institutions: Addenbrookes
Hospital, Cambridge; University Hospitals Birmingham
NHS Foundation Trust; University Hospitals of Leicester
NHS Trust; St. Vincent’s University Hospital, Dublin;
University Hospital Galway, Galway; Burney Breast Unit,
St Helens and Knowsley Teaching Hospital NHS Trust,
Liverpool; Guy’s and St Thomas’ NHS Foundation Trust,
London; Ninewells Hospital, Dundee; University of Turin,
Turin Italy. Patients with tumours that demonstrated an
HER2 IHC score of 2+ but that were non-amplified with
FISH were included as a control group (n= 151).
Patients were considered eligible for anti-HER2 therapies
if their tumours showed a HER2 IHC score of 3+, or 2+
with a ratio ≥2.0 regardless of the HER2 CN or if the HER2
gene CN was ≥6, as recommended by UK guidelines
(corresponding to ASCO/CAP FISH Groups 1, 2 and 3)
[19]. Treatment was given according to institutional
guidelines. Exact neoadjuvant regimens and number of
cycles varied slightly but patients were divided into four
groups according to the neoadjuvant treatment received:
chemotherapy alone; chemotherapy with trastuzumab;
chemotherapy with dual anti-HER2 agents (i.e. trastuzumab
with either pertuzumab or lapatinib) and anti-HER2
therapy alone.
pCR was defined as no residual invasive carcinoma in
both breast and axillary lymph nodes regardless of the
presence of residual DCIS (ypT0/is ypN0) [8]. Histological
grade was evaluated according to the Nottingham mod-
ification of the Scarff-Bloom-Richardson system on the pre-
treatment specimens [20]. All of the histopathological data
used in the analysis were derived from the original
pathology reports.
Immunohistochemistry and FISH assay
IHC for ER and progesterone receptor (PR), and both
HER2 IHC and FISH for HER2 in pre- and post-treatment
Table 1 HER2 FISH groups in 2018 ASCO/CAP guidelines.




4 <2.0 ≥4.0 and <6.0
5 <2.0 <4.0
CN copy number.
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specimens were assessed as per UK guidelines [19, 21].
HER2 IHC was scored as positive (3+), equivocal (2+) or
negative (1+/0), and IHC score 2+ patients were tested
for HER2 amplification by FISH [19]. As per the 2018
ASCO/CAP guidelines, HER2 FISH status was assigned
to one of five groups (Table 1) [5]. However, it was
impossible to completely follow the recommendation for
concomitant IHC review and reassessment and recounting
of FISH slides in the less common FISH patterns (Groups
2, 3 and 4) owing to the retrospective nature of this study.
In this study, ASCO/CAP FISH Groups 1, 2 and 3 were
defined as HER2 amplified according to UK guidelines,
which differ from 2018 ASCO/CAP guidelines where
Group 2 tumours are now considered non-amplified [19].
According to CEP17 CN, chromosome 17 (chr 17) status
was defined as monosomy of chr17 (m17) if <1.5, normal
chr17 (n17) if ≥1.5 but <3.0, and polysomy of chr17 (p17)
if ≥3.0 average CN per carcinoma cells [22, 23]. For
ER and PR, tumours were classified as positive when
there was ≥1 % nuclear staining in invasive carcinoma
cells [21].
Statistical analysis
Statistical analysis was performed using EZR (Saitama
Medical Center Jichi Medical University; http://www.jichi.
ac.jp/saitama-sct/SaitamaHP.files/statmed.html), which is a
graphical user interface for R (The R Foundation for Sta-
tistical Computing, Vienna, Austria, version 2.13.0) [24].
Associations between clinicopathological variables and
pCR were examined with Fisher’s exact tests or Pearson’s
χ2 test, as appropriate. A logistic regression model was
applied to evaluate the effect of covariates on pCR. If a
variable remained at a level of p value ≤ 0.15, it was
incorporated into the final multivariable model [25]. Com-
parison between pre- and post-treatment receptor status was
assessed by McNemar’s test. A p value ≤ 0.05 was con-
sidered statistically significant. This study was approved by
the Nottingham Research Tissue Bank Access Committee




Table 2 shows the demographic and treatment character-
istics of the study cohort by HER2 categories. The median
age at diagnosis was similar amongst all the groups. The
tumour histological type was most commonly invasive
breast carcinoma of no special type (NST), whilst histolo-
gical grade was predominantly 2 or 3 across the whole
cohort. ER and PR were both more often negative in IHC 3+
tumours than in other groups (p < 0.001). As expected,
patients with HER2-positive tumours were significantly
more likely to receive anti-HER2 therapy (p < 0.001).
Chemotherapy with trastuzumab was the main neoadjuvant
treatment in patients with tumours that were HER2 IHC 3+
or IHC 2+ within the HER2 amplified group (ASCO/CAP
FISH Groups 1, 2 and 3), while all patients within the HER2
non-amplified group (Groups 4 and 5) received chemother-
apy alone. An anthracycline- and taxane-based chemotherapy
regimen was received by the majority of patients across all
groups, but the number of patients treated without an
anthracycline regimen was significantly higher in Group 1
(p < 0.001).
HER2 categories and pathologic complete response
Comparisons of pCR rate within the HER2 categories were
made according to ER and PR status and whether anti-
HER2 therapy was given (Fig. 1). For whole patients,
relationship between treatment regimens and pCR rate
among various HER2 categories was different (Fig. 1A).
For IHC 3+ tumours, the pCR rate was 37.5% (n= 6/16)
for patients treated with chemotherapy alone and 51.8%
(85/164) following anti-HER2 therapy. Among IHC 2+
tumours, the pCR rate following chemotherapy alone was as
follows: 12.5% (2/16) in the HER2 amplified group (Groups
1, 2 and 3); 12.5% (1/8) in Group 1; 16.7% (1/6) in Group
2; 0% (0/2) in Group 3; 12.6% (19/151) in the HER2 non-
amplified group (Groups 4 and 5). The pCR rate in IHC 2+
tumours when anti-HER2 therapy was also given was as
follows: 20.3% (31/153) in HER2 amplified tumours
(Groups 1, 2 and 3); 20.2% (21/104) in Group 1; 21.4% (9/
42) in Group 2; and 14.3% (1/7) in Group 3. Thus, IHC 3+
tumours had higher rates of pCR than IHC 2+/HER2
amplified tumours, when either in receipt of chemotherapy
alone (37.5% versus 12.5%; p= 0.22) or anti-HER2 ther-
apy (51.8% versus 20.3%; p < 0.001).
We then evaluated the likelihood of pCR following
different anti-HER2 therapies (chemotherapy plus single
anti-HER2 therapy or chemotherapy plus dual anti-HER2
therapy) for HER2-positive tumours (Fig. 1B). Whether
treated with chemotherapy plus single or chemotherapy
plus dual anti-HER2 therapy, patients with IHC 3+
tumours had a significantly higher pCR rate than those
with the IHC 2+/HER2 amplified tumours (pCR rate in
chemo+anti-HER2-single, 50.0% in IHC 3+ versus
19.4% in IHC 2+/HER2 amplified; p < 0.001) (pCR rate
in chemo+anti-HER2-dual, 59.3% in IHC 3+ versus
17.6% in IHC 2+/HER2 amplified; p= 0.01). For IHC3+
tumours, chemotherapy plus dual anti-HER2 therapy
showed higher pCR rate than chemotherapy plus single
anti-HER2 therapy (59.3% versus 50.0%; p= 0.41).
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For patients who received anti-HER2 therapy (Fig. 1C,
D), those who had ER-negative tumours showed a sig-
nificantly higher pCR rate than those who had ER-positive
tumours in Group 1 (p= 0.01). PR status did not sig-
nificantly affect the pCR rate.
Prediction of pCR according to HER2 categories
The association between clinicopathological and treatment
parameters and the attainment of a pCR was examined in
the whole cohort, in the different HER2 categories and in
Table 2 Patients baseline characteristics.
Characteristic IHC3+ (n=
180) No. (%)












Median [range] 52 [23–83] 52 [27–86] 52 [27–78] 50 [36–71] 54 [23–73] 53 [26–75]
Histology type
Ductal, NST 160 (88.9) 97 (86.6) 43 (89.6) 9 (100) 48 (87.3) 83 (86.5) 0.45
Special types 7 (3.9) 8 (7.1) 2 (4.2) 0 4 (7.3) 1 (1.0)
Lobular 6 (3.3) 6 (5.4) 2 (4.2) 0 3 (5.4) 9 (9.4)
Mixed (ductal and
lobular)
4 (2.2) 1 (0.9) 0 0 0 3 (3.1)
Unknown 3 (1.7) 0 1 (2.0) 0 0 0
Histological grade
1 2 (1.1) 1 (0.9) 1 (2.1) 0 1 (1.8) 2 (2.1) 0.17
2 103 (57.2) 55 (49.1) 26 (54.2) 3 (33.3) 25 (45.5) 64 (66.7)
3 64 (35.6) 52 (46.4) 20 (41.6) 6 (66.7) 29 (52.7) 28 (29.1)
Unknown 11 (6.1) 4 (3.6) 1 (2.1) 0 0 2 (2.1)
ER
Positive 103 (57.2) 87 (77.7) 35 (72.9) 9 (100) 44 (80.0) 72 (75.0) <0.001
Negative 75 (41.7) 25 (22.3) 13 (27.1) 0 11 (20.0) 24 (25.0)
Unknown 2 (1.1) 0 0
PR
Positive 69 (38.3) 51 (45.5) 21 (43.8) 7 (77.8) 28 (50.9) 53 (55.2) <0.001
Negative 110 (61.1) 37 (33.1) 15 (31.2) 2 (22.2) 15 (27.3) 36 (37.5)
Unknown 1 (0.6) 24 (21.4) 12 (25.0) 0 12 (21.8) 7 (7.3)
Neoadjuvant treatments
Chemotherapy alone 16 (8.9) 8 (7.1) 6 (12.5) 2 (22.2) 55 (100) 96 (100) <0.001
Chemotherapy+anti-
HER2 therapy (single)
134 (74.4) 87 (77.7) 37 (77.1) 5 (55.6) 0 0
Chemotherapy+dual anti-
HER2 therapy
27 (15.0) 13 (11.6) 3 (6.2) 1 (11.1) 0 0




128 (72.3) 66 (61.1) 36 (78.3) 5 (62.5) 44 (80.0) 75 (78.1) <0.001
Anthracyclines without
Taxanes
32 (18.1) 6 (5.6) 2 (4.3) 1 (12.5) 6 (10.9) 17 (17.7)
Non-anthracyclines 17 (9.6) 36 (33.3) 8 (17.4) 2 (25.0) 5 (9.1) 4 (4.2)
According to 2018 ASCO/CAP guidelines, HER2 FISH status were divided into five groups in IHC 2+ patients: group 1, HER2/CEP17 ratio ≥
2.0, average HER2 gene CN ≥ 4.0; group 2, HER2/CEP17 ratio ≥ 2.0, HER2 gene CN < 4.0; group 3, HER2/CEP17 ratio < 2.0, HER2 gene CN >
6.0; group 4, HER2/CEP17 ratio < 2.0, average HER2 gene CN ≥ 4.0 and ≤6.0; and group 5, HER2/CEP17 ratio < 2.0, HER2 gene CN < 4.0.
Bold values indicate statistical significance p < 0.05.
IHC immunohistochemistry, NST no special type.
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those who received anti-HER2 therapy by univariate and
multivariate stepwise regression model (Table 3). Within
the cohort of patients with IHC 3+ tumours, pCR was not
associated with any additional factor studied. Among those
with IHC 2+/HER2 amplified tumours (Groups 1, 2 and 3),
ER-negativity was identified as an independent predictor of
pCR (ER negative versus positive; OR, 11.80; 95%CI,
1.38–101.00; p= 0.02) which remained the case in Group 1
alone (ER negative versus positive; OR, 3.71; 95% CI,
1.28–10.70; p= 0.02). In Group 2, histological grade 3 was
an independent predictor of pCR (3 versus 1, 2; OR, 7.86;
95% CI, 1.39–44.40; p= 0.02). For patients treated with
anti-HER2 therapy, histological grade 3 (3 versus 1, 2; OR,
1.750; 95% CI, 1.02–3.01; p= 0.04) and HER2 IHC 3+
(IHC 3+ versus IHC 2+/HER2 amplified; OR, 3.490;
95% CI, 1.98–6.16; p < 0.001) were identified as independent
predictors of pCR.
Changes in ER, PR and HER2 status after
neoadjuvant treatment
HER2 status was assessed in the residual invasive carci-
noma present after NACT and/or neoadjuvant anti-HER2
therapy in 221 patients. For comparison any ER and PR
status changes were also assessed (143, 140 patients
respectively) (Table 4). Of the 139 patients with pre-
treatment HER2-positive tumours (IHC 3+ or IHC 2+/
HER2 amplified), 31 tumours (22.3%) become HER2-
negative (IHC 2+/HER2 non-amplified, or IHC 0/1+) after
treatment, whereas 13/82 (15.9%) of patients with HER2-
negative tumours before treatment changed to HER2-
positive following treatment (p= 0.01). In our cohort,
neoadjuvant treatment regimens were not significantly
associated with changes to post-neoadjuvant HER2 cate-
gories (data not shown). None of the 101 ER-positive
tumours before treatment changed to ER-negative after
treatment, whereas 4/42 (9.5%) of patients with pre-
treatment ER-negative tumours changed to ER-positive.
Of the 76 patients with PR-positive tumours before treat-
ment, 15 (19.7%) had PR-negative tumours after treatment,
whereas 11/64 (17.2%) patients with PR-negative tumours
before treatment changed to PR-positive. These differences
were not significant (p > 0.05).
We then evaluated HER2 concordance between pre- and
post-treatment specimens according to the different HER2
categories (Table 5). The highest level of concordance
(78.4%) was observed for IHC3+ tumours followed by
55.2% in ASCO/CAP FISH Group 2. No tumours within
ASCO/CAP FISH Groups 1, 2 or 3 in the pre-treatment
specimen were assessed IHC 3+ in the post-treatment
excision specimen. Focussing on the 5 ASCO/CAP FISH
groups, 62 patients (45.6%) showed a change in the FISH
group pre- and post-treatment; 9.6% of HER2 amplified
tumours (Groups 1, 2 and 3) changed FISH group whilst,
16.9% of HER2 non-amplified tumours (Groups 4 and 5)
changed. The ASCO/CAP FISH group was unchanged in
54.4% of patients. Importantly, 38.1% (16/42) of tumours
that were identified as being within Group 1 in the pre-
treatment specimen changed to HER2 non-amplified group
in the excision specimen.
Focusing on the average HER2 gene and CEP17 CNs,
we evaluated HER2 discordance between pre- and post-
Fig. 1 The pathological complete response rate in HER2 categories. (A) according to types of neoadjuvant treatment for whole patients,
(B) different anti-HER2 therapies for HER2-positive patients, (C) ER status for anti-HER2 therapy given patients, and (D) PR status for anti-HER2
therapy given patients.
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Table 3 Univariate and multivariate logistic regression model for pCR according to HER2 categories or anti-HER2 therapy given.





OR 95% CI P value OR 95% CI P value
IHC 3+
Age ≥50/<50 47/54 (46.5) 42/34 (49.4) 0.71 0.39–1.28 0.29 – – –
Histological grade 3/1, 2 36/28 (56.2) 47/58 (62.7) 1.59 0.85–2.97 0.16 – – –
ER Negative/positive 38/37 (50.6) 51/52 (49.5) 1.05 0.58–1.90 1 – – –
PR Negative/positive 57/53 (51.8) 33/36 (47.8) 1.17 0.64–2.14 0.65 – – –





81/79 (50.6) 8/9 (47.1) 1.15 0.42–3.14 0.80 – – –
HER2 amplified group (Groups 1, 2 and 3)
Age ≥50/<50 19/81 (19.0) 14/54 (20.6) 0.91 0.42–1.96 0.85 – – –
Histological grade 3/1, 2 23/55 (29.5) 10/76 (11.6) 3.18 1.40–7.21 0.006 2.10 0.83–5.36 0.12
ER Negative/positive 15/23 (39.5) 18/113 (13.7) 4.09 1.81–9.29 <0.001 11.80 1.38–101.00 0.02
PR Negative/positive 15/39 (27.8) 13/66 (16.5) 1.95 0.84–4.53 0.133 0.252 0.03–2.07 0.20





20/96 (17.2) 10/36 (21.7) 0.75 0.32–1.76 0.51 – – –
FISH Group 1
Age ≥50/<50 14/52 (21.2) 8/38 (17.4) 1.28 0.49–3.35 0.81 – – –
Histological grade 3/1, 2 14/38 (26.9) 8/48 (14.3) 2.21 0.84–5.82 0.15 1.58 0.56–4.45 0.39
ER Negative/positive 10/15 (40.0) 12/75 (13.8) 4.17 1.52–11.40 0.008 3.71 1.28–10.70 0.02
PR Negative/positive 11/26 (29.7) 9/42 (17.6) 1.97 0.72–5.41 0.21 – – –





12/60 (16.7) 9/27 (25.0) 0.6 0.23–1.59 0.31 – – –
FISH Group 2
Age ≥50/<50 4/25 (13.8) 6/13 (31.6) 0.35 0.08–1.45 0.16 – – –
Histological grade 3/1, 2 8/12 (40.0) 2/25 (7.4) 8.33 1.53–45.40 0.01 7.86 1.39–44.40 0.02
ER Negative/positive 5/8 (38.5) 5/30 (14.3) 3.75 0.87–16.20 0.11 3.27 0.66–16.30 0.15
PR Negative/positive 4/11 (26.7) 3/18 (14.3) 2.18 0.41–11.60 0.42 – – –





7/31 (18.4) 1/7 (12.5) 1.58 0.17–15.00 1.00 – – –
Anti-HER2 therapy given
Age ≥50/<50 59/121 (32.8) 55/78 (41.4) 0.69 0.43–1.10 0.12 0.71 0.42–1.22 0.22
Histological grade 3/1, 2 55/78 (41.4) 53/116 (31.4) 1.54 0.96–2.48 0.09 1.75 1.02–3.01 0.04
ER Negative/positive 47/57 (45.2) 67/144 (31.8) 1.77 1.09–2.87 0.02 1.34 0.64–2.82 0.43
PR Negative/positive 64/85 (43.0) 46/88 (34.3) 1.44 0.89–2.33 0.15 1.07 0.52–2.21 0.86





93/152 (38.0) 18/44 (29.0) 1.50 0.82–2.74 0.24 – – –
According to 2018 ASCO/CAP guidelines, HER2 FISH status were divided into five groups in IHC 2+ patients: group 1, HER2/CEP17 ratio ≥ 2.0,
average HER2 gene CN ≥ 4.0; group 2, HER2/CEP17 ratio ≥ 2.0, HER2 gene CN < 4.0; group 3, HER2/CEP17 ratio < 2.0, HER2 gene CN > 6.0;
group 4, HER2/CEP17 ratio < 2.0, average HER2 gene CN ≥ 4.0 and <6.0; and group 5, HER2/CEP17 ratio < 2.0, HER2 gene CN < 4.0.
Bold values indicate statistical significance p < 0.05.
IHC immunohistochemistry, FISH fluorescence in situ hybridisation, pCR pathological complete response, OR odds ratio, CI confidence interval.
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treatment specimens among the IHC 2+ tumours (Table 6).
Of the 23 patients that changed HER2 category from
IHC2+/HER2 amplified to IHC2+/HER2 non-amplified,
15 (65.2%) maintained the same HER2 gene CN, whereas
8 (34.8%) showed a decreased HER2 gene CN. In addi-
tion, chr 17 status was divided into m17, n17 and p17
according to CEP17 CN. Of the previously mentioned 23
patients, 17 (73.9%) maintained the same chr 17 status,
while 2 (8.7%) patients with n17 before treatment changed
to p17 after treatment. For comparison 13 patients
that changed category from an IHC2+/HER2 non-
amplified to IHC2+/HER2 amplified were assessed; of
the 13 patients, 10 (76.9%) maintained the same HER2
gene CN, whereas 3 (23.1%) showed an increased HER2
gene CN. According to CEP17 CN, of the 13 patients,
10 (76.9%) maintained the same chr 17 status, while
1 (7.7%) with n17 before treatment changed to m17.
Discussion
In the current study, we aimed to identify predictive factors
for pCR after NACT across different HER2-positive cate-
gories. We showed that HER2 IHC 3+ invasive BC had a
higher pCR rate than IHC 2+/HER2 amplified tumours
when anti-HER2 therapy was received, consistent with
earlier analyses [9]. In our study, pCR rate of HER2 IHC 3
+ tumours following anti-HER2 therapy was 52%, within
the range reported in clinical trials with similar treatment
regimens; for example, pCR rate was 38% in the NOAH
trial using NACT with trastuzumab, 39% in the NeoSphere
and 58% in the TRYPHAENA trials using NACT with
trastuzumab and pertuzumab [10, 26, 27]. In keeping with
the significant impact on pCR that dual anti-HER2 therapy
has shown [26–28], we also identified a higher pCR rate for
NACT with dual anti-HER2 therapy compared to NACT
with single ani-HER2 therapy in patients with IHC 3+ BC.
Notably, the pCR rates among HER2 IHC 2+/HER2
amplified tumours in patients who received anti-HER2
therapy were 20% in Group 1, 21% in Group 2 and 14% in
Group 3, lower than the clinical trials. Regardless of ASCO/
CAP FISH groups, IHC 2+/HER2 amplified tumours
showed significantly lower rates of pCR than IHC 3+
tumours. Consistent with previous studies, our data high-
light that HER2 IHC 3+ and histological grade 3 are
independent predictors of pCR following treatment with
anti-HER2 therapy [9, 29]. Although a higher rate of pCR
in HER2 IHC 3+ tumours was reported in the



















IHC 3+ 65 (29.4) 51 (78.4) 4 (6.2) 2 (3.0) 0 0 4 (6.2) 4 (6.2)
IHC 2+
Group 1 42 (19.0) 0 21 (50.0) 5 (11.9) 0 4 (9.5) 12 (28.6) 0
Group 2 29 (13.1) 0 7 (24.1) 16 (55.2) 0 0 6 (20.7) 0
Group 3 3 (1.4) 0 1 (33.3) 0 1 (33.3) 1 (33.3) 0 0
Group 4 27 (12.2) 0 4 (14.9) 1 (3.7) 0 11 (40.7) 11 (40.7) 0
Group 5 55 (24.9) 0 5 (9.1) 3 (5.4) 0 2 (3.6) 25 (45.5) 20 (36.4)
According to 2018 ASCO/CAP guidelines, HER2 FISH status were divided into five groups in IHC 2+ patients: group 1, HER2/CEP17 ratio ≥
2.0, average HER2 gene CN ≥ 4.0; group 2, HER2/CEP17 ratio ≥ 2.0, HER2 gene CN < 4.0; group 3, HER2/CEP17 ratio < 2.0, HER2 gene CN >
6.0; group 4, HER2/CEP17 ratio < 2.0, average HER2 gene CN ≥ 4.0 and ≤6.0; and group 5, HER2/CEP17 ratio < 2.0, HER2 gene CN < 4.0.
Bold values indicate statistical significance p < 0.05.
IHC immunohistochemistry.
Table 4 Comparison of HER2, ER and PR status between the pre-
treatment core biopsy and the post-treatment excision specimen.






Positive 139 (62.9) 108 (77.7) 31 (22.3) 0.01
Negative 82 (37.1) 13 (15.9) 69 (84.1)
ER
Positive 101 (70.6) 101 (100) 0 0.13
Negative 42 (29.4) 4 (9.5) 38 (90.5)
PR
Positive 76 (54.3) 61 (80.3) 15 (19.7) 0.56
Negative 64 (45.7) 11 (17.2) 53 (82.8)
Bold values indicate statistical significance p < 0.05.
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Krystel–Whittemore study [9], their cohort had higher
proportions of histological grade 3, ER negative and
patients who received dual anti-HER2 therapy. This is in
keeping with our analysis of the HER2 IHC 3+ tumours
that confirmed that a higher pCR rate was seen in histolo-
gical grade 3 tumours treated with NACT and dual anti-
HER2 therapy (64%).
Overall, in the HER2 IHC 2+/HER2 amplified group
treated with NACT and/or anti-HER2 therapy, ER-
negativity was an independent predictor of pCR. Further-
more, we identified independent predictors of pCR by
ASCO/CAP FISH group treated with NACT and/or anti-
HER2 therapy: ER-negativity in Group 1 and histological
grade 3 in Group 2. Predictors were not seen in the very
small numbers of patients with tumours in Group 3. Indeed,
because Groups 2, 3 and 4 are uncommon, the response of
tumours in the different ASCO/CAP FISH groups to NACT
has not been well explored [30]. Further analyses using a
larger cohort are needed to validate these results, however
our findings provide preliminary evidence that predictors of
pCR differ between the ASCO/CAP FISH groups.
Hormone receptor (HR) status influences the response of a
tumour to chemotherapy and the sensitivity of a tumour to
combined chemotherapy and anti-HER2 therapy also differs
according to HR status in the neoadjuvant setting [9–12, 31].
Because HER2-positive, HR-negative tumours are likely to be
highly dependent on the HER2 gene for growth, these
tumours typically show a good response to anti-HER2
therapies [32]. In the present series, in patients who
received anti-HER2 therapy, ER-negativity was significantly
associated with pCR in univariate analysis, but was not an
independent predictive factor in multivariate analysis. We
observed that HER2 IHC 2+/HER2 amplified ER-negative
tumours showed a significantly higher rate of pCR than HER2
amplified ER-positive tumours. Meanwhile, in HER2 IHC 3+
tumours neither ER-negative nor PR-negative subgroups had
a significantly higher rate of pCR, similar to the findings of
Miolo et al [33]. It has been previously reported that patho-
logical characteristics differ between HER2 IHC 3+ and
HER2 IHC 2+/HER2 amplified tumours: IHC 3+ tend to be
of higher histological grade, larger tumour size, and are often
ER-negative and PR-negative [34]. These findings emphasise
the importance of considering combined HER2 and HR status
to select those patients most likely to benefit from neoadju-
vant anti-HER2 therapy.
Despite lower rates of pCR in HER2-positive/HR-posi-
tive tumours, it has been reported that these tumours have a
good prognosis, and that there is thus a weaker association
between pCR and long-term outcome in HER2-positive/
HR-positive tumours than HER2-positive/HR-negative
tumours [8, 35]. However, neoadjuvant endocrine therapy
for HER2-positive/HR-positive patients has not resulted in a
marked improvement in pCR rate [35]. Further strategies
are required to increase the pCR rate and improve outcome
in patients with HER2-positive/HR-positive BC.
Our results again highlight variation in HER2, ER and PR
status in some cancers before and after neoadjuvant treatment,
although the reported frequency of this varies [13–18]. The
changes in HER2 status with loss of HER2 expression in the
post-treatment specimens was statistically significant. This
may reflect the response of the HER2 positive clone in the
tumour to NACT and/or anti-HER2 therapy, leaving the HER2
negative clone as a residual component. Similarly, the acqui-
sition of HER2 positivity post treatment in a few cases is likely
to reflect heterogeneity of HER2 expression. Of note, however,
there was less frequent change in HER2 status following
Table 6 Correlation between HER2 gene CN and CEP17 CN in pre-treatment core biopsy and the post-treatment excision specimen among HER2
discordant patients.
Pre-treatment Post-treatment
HER2 discordance (HER2 amplified to non-amplified)
(n= 23)
HER2 discordance (HER2 non-amplified to amplified)
(n= 13)
HER2 gene CN HER2 gene CN
HER2 gene CN <6.0 No. (%) ≥6.0 No. (%) <6.0 No. (%) ≥6.0 No. (%)
<6.0 15 (65.2) 0 10 (76.9) 3 (23.1)
≥6.0 8 (34.8) 0 0 0
CEP17 CN CEP17 CN












m17 (<1.5) 1 (4.3) 2 (8.7) 0 1 (7.7) 1 (7.7) 0
n17 (≥1.5, <3.0) 0 15 (65.2) 2 (8.7) 1 (7.7) 9 (69.2) 0
p17 (≥3.0) 0 2 (8.7) 1 (4.3) 0 1 (7.7) 0
CN copy number, m17 monosomy chromosome 17, n17 normal chromosome 17, p17 polysomy chromosome 17.
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neoadjuvant NACT and/or anti-HER2 therapy in cases defined
as definitely positive by IHC (HER2 IHC 3+) on pre-treatment
specimens, compared to those that were IHC 2+. It is unclear
whether loss of HER2 amplification reflects response to ther-
apy, a mechanism of resistance or heterogeneity of HER2
expression [14]. If such changes in HER2 status will affect
post-neoadjuvant treatment decisions, such as the tailoring of
subsequent adjuvant therapy, based on these results, we sug-
gest that HER2 should be re-tested in post-neoadjuvant sur-
gical specimens, particularly in HER2 2+/HER2 amplified
tumours. Moreover, it has been reported that such alterations
provide prognostic information with loss of HER2-positivity in
residual tumours after neoadjuvant treatment shown to be
associated with a poorer outcome compared with tumours with
preserved HER2-positive status [16–18].
Our study has some limitations. First, this was a retro-
spective non-randomised study, and our samples were col-
lected from multiple institutions which may have some
selection bias effect. Second, some subset analyses were
underpowered to detect subgroup differences due to small
sample size, especially those in HER2 2+/FISH Group 3 BC
(n= 9). Third, because of differences in regimens of che-
motherapy prescribed, the influence of those on the different
HER2-positive groups of BC with respect to pCR needs
further study. Finally, not all patients with HER2-positive
tumours received anti-HER2 therapy in this cohort; some
patients, including some older women with co-morbidities
and those with small and node-negative HER2-positive
tumours, were less likely to receive neoadjuvant anti-HER2
therapy. In our cohort, there were no significantly differences
in clinicopathological features such as age, HR status and
histological grade whether anti-HER2 therapy given or not
(Table 7). Special tumour type was a high percentage in
patients received chemotherapy alone (p= 0.04).
In conclusion, the data presented here indicate that the
maximum benefit of neoadjuvant anti-HER2 therapy is
observed in the subgroup of patients with tumours that are
HER2 IHC 3+, histological grade 3 or IHC 2+/HER2
amplification co-existing with ER-negativity. Among
tumours that were HER2 IHC 2+/HER2 amplified, the
predictors of pCR were different in the various ASCO/CAP
FISH groups. In our study, 22% of HER2-positive tumours
before treatment changed to HER2-negative after neoadju-
vant treatment, more commonly in HER2 IHC 2+/HER2
amplified tumours, especially ASCO/CAP FISH Group 1.
Reassessment of HER2 status following neoadjuvant treat-
ment should be considered in patients in whom it will
facilitate further management decisions.
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Table 7 HER2-positive patient baseline characteristics between
neoadjuvant chemotherapy alone and anti-HER2 therapy given.









Median [range] 53 [29–80] 52 [23–86]
Histology type
Ductal, NST 24 (75.0) 285 (89.9) 0.04
Special types 4 (12.5) 13 (4.1)




Unknown 1 (3.1) 3 (0.9)
Histological grade
1 1 (3.1) 3 (0.9) 0.18
2 21 (65.7) 166 (52.4)
3 9 (28.1) 133 (42.0)
Unknown 1 (3.1) 15 (4.7)
ER
Positive 23 (71.9) 211 (66.6) 0.69
Negative 9 (28.1) 104 (32.8)
Unknown 0 2 (0.6)
PR
Positive 14 (43.7) 134 (42.3) 1
Negative 15 (46.9) 149 (47.0)
Unknown 3 (9.4) 34 (10.7)
Bold values indicate statistical significance p < 0.05.
NST no special type.
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